US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

27.20

+0.76282.89%

Volume:696

Turnover:18.95K

Market Cap:2.45M

PE:- -

High:27.23

Open:27.15

Low:27.15

Close:26.44

52wk High:28.89

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:0.74

T/O Rate:0.77%

Dividend:0.68

Dividend Rate:2.50%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

4basebio Strikes Genezen Pact to Advance Synthetic DNA for Viral Vector Manufacturing

BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

Press Release: Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment

Press Release: Fosun Pharma Announces 2026 Interim Results

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

GlucoTrack subsidiary initiates clinical trial manufacturing for LT-100

Sagimet Biosciences advances AURORA clinical trial

Savara announces presentations of Results from Phase 3 trial of Molgramostim

Syngenis banks R&D refund to fuel biotech build-out

The West Australian

Ribomic Completes Site Network for Phase 3 Achondroplasia Trial in Japan

Moderna’s Shock Rally Redraws the Biotech Playbook

Press Release: 3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth

Press Release: Sunshine Guojian Releases 2026 Interim Report:

Regeneron’s Pasatru granted FDA approval for FOP

VOOLT boosts deeptech portfolio with stake in cancer-vaccine biotech Vaxican

BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

Arctic Bioscience Sets Date for H1 2026 Results and Investor Webcast

Glenmark Wins U.S. FDA Nod for Generic Flonase Nasal Spray

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/NVIB/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":27.1999,"timestamp":1789675200000,"preClose":26.4371,"halted":0,"volume":696,"delay":0,"changeRate":0.028853391635239818,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Pre-Mkt","change":0.7628,"latestTime":"09-18 08:11:21 EDT","open":27.15,"high":27.229,"low":27.15,"amount":18953,"amplitude":0.002988,"askPrice":43.51,"askSize":200,"bidPrice":10.88,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789738200000},"marketStatusCode":1,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":27.1999,"nav":26.486,"aum":2383782.07,"dividendRate":0.025011,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":27.229,"preClose":27.1999,"latestTime":"16:10 EDT","volume":6,"amount":163.1994,"timestamp":1789675804313,"change":0.0291,"changeRate":0.00107,"amplitude":0},"volumeRatio":0.7407406697885693},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.7407406697885693,"shares":90001,"dividePrice":0.6803,"high":27.229,"amplitude":0.002988,"preClose":26.4371,"low":27.15,"week52Low":24.54,"pbRate":"--","week52High":28.8896,"institutionHeld":0,"latestPrice":27.1999,"eps":0,"divideRate":0.025011,"volume":696,"delay":0,"ttmEps":0,"open":27.15,"prevYearClose":25,"prevWeekClose":27.3696,"prevMonthClose":27.4504,"prevQuarterClose":25,"fiveDayClose":27.3569,"twentyDayClose":27.1043},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-09-15","symbol":"NVIB","amount":0.22766,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-16","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-16"},{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"},{"executeDate":"2026-09-15","recordDate":"2026-09-15","paymentDate":"2026-09-16","value":0.22766,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662471428","title":"Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662471428","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662471428?lang=en_us&edition=fundamental","pubTime":"2026-08-26 20:30","pubTimestamp":1787747400,"startTime":"0","endTime":"0","summary":"If approved, REVTORPYK would be the first and only therapy for advanced breast cancer with a PIK3CA mutation that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 M","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351327/0/en/celcuity-submits-snda-to-fda-for-revtorpyk-gedatolisib-for-hr-her2-pik3ca-mutant-locally-advanced-or-metastatic-breast-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRET","LU0757428866.USD","BK4585","LU2931357623.SGD","LU1815336091.USD","LU0274383776.USD","GDOC","IE00B19Z4B17.USD","LABU","BK4225","NVIB","LU1878469433.USD","ALT","IE00B66KJ199.SGD","BK4588","BK4203","BK4157","BK4139","IDNA","IE00B7SZL793.SGD","HR","IE0031619046.USD","HYLG","AEIS","BK4599","LU2089985449.USD","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662760410","title":"4basebio Strikes Genezen Pact to Advance Synthetic DNA for Viral Vector Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2662760410","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662760410?lang=en_us&edition=fundamental","pubTime":"2026-08-26 14:13","pubTimestamp":1787724830,"startTime":"0","endTime":"0","summary":"4basebio UK Societas ( ($GB:4BB) ) has issued an update. 4basebio PLC, a UK-listed biotech focused on synthetic, cell-free DNA and mRNA for advance...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/4basebio-strikes-genezen-pact-to-advance-synthetic-dna-for-viral-vector-manufacturing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/4basebio-strikes-genezen-pact-to-advance-synthetic-dna-for-viral-vector-manufacturing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DNA","BK4121","XBIX","BK4561","VAQC","NVIB","BK4109","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662530687","title":"BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA","url":"https://stock-news.laohu8.com/highlight/detail?id=2662530687","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662530687?lang=en_us&edition=fundamental","pubTime":"2026-08-25 22:45","pubTimestamp":1787669120,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) announced that the U.S. FDA has approved the supplemental Biologics License Application for TEVIMBRA in combination with ZIIH...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-announces-fda-approval-for-tevimbra-based-reginmen-for-her2-gea-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-announces-fda-approval-for-tevimbra-based-reginmen-for-her2-gea-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNY","TBXU","RSPH","PINK","LABU","IBB","BK4139","BK4588","IDNA","ONC","IYH","BK4526","BK4585","TECB","SYNB","NVIB","FRTY","LFSC","BMED","IEIH","PSCH","GDOC","MRNX","MEDI","XLVX","GNMX","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662175807","title":"U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2662175807","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662175807?lang=en_us&edition=fundamental","pubTime":"2026-08-25 22:23","pubTimestamp":1787667780,"startTime":"0","endTime":"0","summary":"Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, providing a new treatment option in front-li","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350636/0/en/u-s-fda-approves-ziihera-zanidatamab-hrii-with-and-without-tislelizumab-plus-chemotherapy-in-first-line-her2-advanced-gastroesophageal-adenocarcinoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTCZ","BTCI","BRRR","CBTY","CBXJ","LABU","IBIT","MAXI","YBTC","BTCW","GDOC","BITY","BTCO","BITO","MNRS","DEFI","HODL","BITI","EZBC","CBXO","BFAP","CBOJ","CBTA","CBTJ","BMED","IDNA","AEIS","CBOA","BITX","BITU","BTCL","CBTO","BTRN","BCCC","CBOY","FBTC","BFJL","SBIT","NVIB","CRC","BTCC","BPI","XBTY","BTF","DFII","BTC","ARKB","BITB","CBXY","GBTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662732058","title":"Press Release: Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2662732058","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662732058?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:55","pubTimestamp":1787662500,"startTime":"0","endTime":"0","summary":"President & CEO, Sabrina Martucci Johnson, discusses the Company's shift to commercial stage, upcoming revenue opportunities, Ovaprene's positive interim Phase 3 results and what could drive value ove","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4584","IDNA","TM","BK4585","HYLG","GDOC","03160","NVIB","BK4604","BK4588","DARE","BK4099","LABU","MEDX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662322847","title":"Press Release: Fosun Pharma Announces 2026 Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2662322847","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662322847?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:44","pubTimestamp":1787661840,"startTime":"0","endTime":"0","summary":"Globalization Accelerates Value Realization of Innovative DrugsSHANGHAI, Aug. 25, 2026 /PRNewswire/ -- On August 25, Fosun Pharma (\"the Company\", stock code: 600196.SH; 02196.HK) announced its interim","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","NVIB","BK0175","R","BK0196","BK0239","BK0183","BK0188","BK0012","BK0060","BK0028","BK0187","BK1191","BK4022","BK1515","BK0096","02196","600196","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662732665","title":"RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662732665","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662732665?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:30","pubTimestamp":1787661000,"startTime":"0","endTime":"0","summary":"PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial The Study Shows Approximately 51% Tumor-Site Drug Extraction, Decreased Systemic Exposure, and Significant Correlation Between ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350436/0/en/renovorx-highlights-peer-reviewed-publication-of-pharmacokinetic-and-pharmacodynamic-pk-pd-data-supporting-tamp-platform-s-targeted-drug-delivery-in-locally-advanced-pancreatic-can.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","RNXT","IE0031619046.USD","BK4218","LU1169589451.USD","BK4183","NVIB","MEDX","HYLG","AEIS","KBWY","LABU","IE0009354923.USD","BK4139","BK4585","IE00B7SZL793.SGD","LU0345780521.USD","BK4157","LU1815336091.USD","LU0274383776.USD","IE00B19Z4B17.USD","PD","ODD","LU1169590202.USD","LU2931357623.SGD","IE00B66KJ199.SGD","LU2089985449.USD","PK","IDNA","BK4181","BK4539","BK4588","LU0345780281.USD","BK4023","IAG","LU0757428866.USD","BK4017"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662873429","title":"GlucoTrack subsidiary initiates clinical trial manufacturing for LT-100","url":"https://stock-news.laohu8.com/highlight/detail?id=2662873429","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662873429?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:15","pubTimestamp":1787660116,"startTime":"0","endTime":"0","summary":"Lokahi Therapeutics, a subsidiary of Glucotrack (GCTK), announced that it has started its initial Good Manufacturing Practice, GMP, manufacturing c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/glucotrack-subsidiary-initiates-clinical-trial-manufacturing-for-lt-100-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/glucotrack-subsidiary-initiates-clinical-trial-manufacturing-for-lt-100-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","MEDX","NVIB","GCTK","EES","BK4082","GDOC","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773162","title":"Sagimet Biosciences advances AURORA clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773162","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662773162?lang=en_us&edition=fundamental","pubTime":"2026-08-25 19:40","pubTimestamp":1787658027,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (SGMT) announced that its AURORA Phase 3 clinical trial of FASN inhibitor denifanstat in moderate to severe acne is on track to...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-advances-aurora-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-advances-aurora-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","MEDX","SGMT","BK4139","HYLG","GDOC","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662206573","title":"Savara  announces presentations of Results from Phase 3 trial of Molgramostim","url":"https://stock-news.laohu8.com/highlight/detail?id=2662206573","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662206573?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:10","pubTimestamp":1787602218,"startTime":"0","endTime":"0","summary":"Savara (SVRA) announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/savara-announces-presentations-of-results-from-phase-3-trial-of-molgramostim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/savara-announces-presentations-of-results-from-phase-3-trial-of-molgramostim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","BBC","HYLG","GDOC","SVRA","PSIL","NVIB","BK4139","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662204407","title":"Syngenis banks R&D refund to fuel biotech build-out","url":"https://stock-news.laohu8.com/highlight/detail?id=2662204407","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662204407?lang=en_us&edition=fundamental","pubTime":"2026-08-24 23:06","pubTimestamp":1787584007,"startTime":"0","endTime":"0","summary":"Biotech hopeful Syngenis Labs has banked a $363,000 R&D tax refund atop a recent $4 million pre-IPO raise, adding non-dilutive firepower as it builds out its Australian RNA and DNA manufacturing platform.","market":"us","thumbnail":"https://images.thewest.com.au/publication/C-22771960/cfe32dd8d5c27df108386c3ef5f67af0dd0eab91.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22771960/cfe32dd8d5c27df108386c3ef5f67af0dd0eab91.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/syngenis-banks-rd-refund-to-fuel-biotech-build-out-c-22771960","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/syngenis-banks-rd-refund-to-fuel-biotech-build-out-c-22771960","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["GLP","XBIX","BK4590","NVIB","BK4144","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661226379","title":"Ribomic Completes Site Network for Phase 3 Achondroplasia Trial in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2661226379","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661226379?lang=en_us&edition=fundamental","pubTime":"2026-08-24 14:54","pubTimestamp":1787554445,"startTime":"0","endTime":"0","summary":"The latest update is out from Ribomic, Inc. ( ($JP:4591) ). Ribomic has completed the establishment of all planned clinical trial sites for its Pha...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ribomic-completes-site-network-for-phase-3-achondroplasia-trial-in-japan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ribomic-completes-site-network-for-phase-3-achondroplasia-trial-in-japan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","MEDX","IDNA","HYLG","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661219445","title":"Moderna’s Shock Rally Redraws the Biotech Playbook","url":"https://stock-news.laohu8.com/highlight/detail?id=2661219445","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661219445?lang=en_us&edition=fundamental","pubTime":"2026-08-22 22:01","pubTimestamp":1787407292,"startTime":"0","endTime":"0","summary":"Moderna ( ($MRNA) ) has risen by 125.15%. Read on to learn why. Moderna has delivered one of the most dramatic moves in biotech this week, with its...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/modernas-shock-rally-redraws-the-biotech-playbook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/modernas-shock-rally-redraws-the-biotech-playbook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","XBI","WDNA","MRNX","GNOM","MRNA","BK4548","BK4551","LGHT","BK4588","IDNA","NVIB","BK4585","MRNY","BK4581","BK4533","BK4501","XBIX","BK4568","BK4534","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661250247","title":"Press Release: 3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2661250247","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661250247?lang=en_us&edition=fundamental","pubTime":"2026-08-21 15:24","pubTimestamp":1787297040,"startTime":"0","endTime":"0","summary":"SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- 3S Bio (01530.HK) today announced its interim results for the first half of 2026. During the period, the Company recorded revenue of RMB 4.53 billion, represent","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","GDOC","HYLG","IDNA","BK1583","BMED","R","BK1161","NVIB","BK4022","BK4232","MEDX","HK0000165453.HKD","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661258777","title":"Press Release: Sunshine Guojian Releases 2026 Interim Report:","url":"https://stock-news.laohu8.com/highlight/detail?id=2661258777","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661258777?lang=en_us&edition=fundamental","pubTime":"2026-08-21 08:00","pubTimestamp":1787270400,"startTime":"0","endTime":"0","summary":"Innovation-driven, Steady AdvancementSHANGHAI, Aug. 20, 2026 /PRNewswire/ -- Today, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as \"Sunshine Guojian\", stock code: 688","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","IDNA","688336","BK1593","HYLG","NVIB","GDOC","BK0239","BK1161","R","BK4232","BK4022","01530","MEDX","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660287604","title":"Regeneron’s Pasatru granted FDA approval for FOP","url":"https://stock-news.laohu8.com/highlight/detail?id=2660287604","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660287604?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:20","pubTimestamp":1787232025,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration has approved Pasatru to reduce new heterotopic ossification and reduce clinician-assessed disease flare-ups i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenerons-pasatru-granted-fda-approval-for-fop-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenerons-pasatru-granted-fda-approval-for-fop-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNY","BK4585","MRNX","XLVX","BMED","BBP","IYH","PSCH","GDOC","LABU","SYNB","NVIB","RSPH","PINK","LFSC","MEDI","GNMX","BK4588","IDNA","FRTY","IEIH","IBB","TBXU","TECB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660845542","title":"VOOLT boosts deeptech portfolio with stake in cancer-vaccine biotech Vaxican","url":"https://stock-news.laohu8.com/highlight/detail?id=2660845542","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660845542?lang=en_us&edition=fundamental","pubTime":"2026-08-20 20:17","pubTimestamp":1787228270,"startTime":"0","endTime":"0","summary":"The latest update is out from VOOLT Spolka Akcyjna ( ($PL:VLT) ). VOOLT S.A. has signed a preliminary agreement to acquire 108 shares in Polish bio...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/voolt-boosts-deeptech-portfolio-with-stake-in-cancer-vaccine-biotech-vaxican?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/voolt-boosts-deeptech-portfolio-with-stake-in-cancer-vaccine-biotech-vaxican?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","NVIB","VLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660288600","title":"BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2660288600","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660288600?lang=en_us&edition=fundamental","pubTime":"2026-08-20 17:30","pubTimestamp":1787218200,"startTime":"0","endTime":"0","summary":"Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any PD-(L)1xVEGF bispecific immunomodulator combined with an antibody-drug conjugate, underscoring BioNT","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/20/3348151/0/en/biontech-highlights-late-stage-lung-cancer-pipeline-momentum-and-first-global-data-for-pumitamig-elfetabart-drozuntecan-novel-novel-combination-at-wclc-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","MEDX","BK4588","BK4585","NVIB","LU2487616109.SGD","LU0053666078.USD","LU0210528500.USD","BK4107","GDOC","IDNA","L"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660835402","title":"Arctic Bioscience Sets Date for H1 2026 Results and Investor Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2660835402","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660835402?lang=en_us&edition=fundamental","pubTime":"2026-08-20 16:08","pubTimestamp":1787213283,"startTime":"0","endTime":"0","summary":"An announcement from Arctic Bioscience AS ( ($DE:9TD) ) is now available. Arctic Bioscience AS, a biotech company specializing in pharmaceutical an...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arctic-bioscience-sets-date-for-h1-2026-results-and-investor-webcast?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arctic-bioscience-sets-date-for-h1-2026-results-and-investor-webcast?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LNGR","XBIX","NVIB","AS","BK4202","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660028408","title":"Glenmark Wins U.S. FDA Nod for Generic Flonase Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2660028408","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660028408?lang=en_us&edition=fundamental","pubTime":"2026-08-20 12:43","pubTimestamp":1787200984,"startTime":"0","endTime":"0","summary":"Glenmark Pharmaceuticals Limited ( ($IN:GLENMARK) ) just unveiled an announcement. Glenmark Pharmaceuticals has secured U.S. FDA approval for its F...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/glenmark-wins-u-s-fda-nod-for-generic-flonase-nasal-spray?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/glenmark-wins-u-s-fda-nod-for-generic-flonase-nasal-spray?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","MRNX","TECB","XLVX","LFSC","MRNY","MEDI","IBB","BBP","IYH","RSPH","IDNA","NVIB","IEIH","BK4585","SYNB","FRTY","TBXU","GNMX","BMED","PINK","LABU","BK4588","PSCH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":195,"code":"91000000","status":"200"}]}}